The concept of oligometastatic esophagogastric cancer (OMC) refers to a clinical picture where the disease has spread beyond the locally-confined stage, however radical local treatment of the metastatic disease could still provide long-term disease control and improve the overall survival compared to systemic metastasized disease.
Up until recently, no consensus had been reached regarding the definition and the treatment strategies for OMC. The available literature does not include randomized controlled trials and the published cohorts are rather inhomogeneous in terms of number of metastases, involved organs, incidence of de-novo OMC and comparison with different treatment strategies.
Progresses have been made in the standardization of the definition of OMC, following the contribution of the European Society for Radiotherapy (ESTRO), the European Organization for Research and Treatment of Cancer (EORTC) and the Oligo Metastatic Esophagogastric Cancer (OMEC) consortium. In this context we encourage the authors to provide relevant literature addressing the following aspects:
- definition, characterization and nomenclature of OMC;
- characterization of distinct biological phenotypes of OMC;
- incidence, treatment strategies and survival of de-novo OMC;
- comparison of different treatment strategies including local radical treatment of OMC plus systemic treatment vs. systemic treatment alone.
Both original research contributions and review articles will be accepted.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
The concept of oligometastatic esophagogastric cancer (OMC) refers to a clinical picture where the disease has spread beyond the locally-confined stage, however radical local treatment of the metastatic disease could still provide long-term disease control and improve the overall survival compared to systemic metastasized disease.
Up until recently, no consensus had been reached regarding the definition and the treatment strategies for OMC. The available literature does not include randomized controlled trials and the published cohorts are rather inhomogeneous in terms of number of metastases, involved organs, incidence of de-novo OMC and comparison with different treatment strategies.
Progresses have been made in the standardization of the definition of OMC, following the contribution of the European Society for Radiotherapy (ESTRO), the European Organization for Research and Treatment of Cancer (EORTC) and the Oligo Metastatic Esophagogastric Cancer (OMEC) consortium. In this context we encourage the authors to provide relevant literature addressing the following aspects:
- definition, characterization and nomenclature of OMC;
- characterization of distinct biological phenotypes of OMC;
- incidence, treatment strategies and survival of de-novo OMC;
- comparison of different treatment strategies including local radical treatment of OMC plus systemic treatment vs. systemic treatment alone.
Both original research contributions and review articles will be accepted.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
